Overview

Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade

Status:
Recruiting

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

Summary

The aim of this randomized study is to compare the efficacy and safety of ondanstron weekly with every 3 weeks for the prevention of nausea and vomiting induced by chemotherapy combined with PD-1 blockade.

Phase:

N/A

Details

Lead Sponsor:

Hubei Cancer Hospital

Treatments:

Aprepitant
Dexamethasone
Ondansetron